"In September 2016, an update research report was published by Baker Young on Actinogen Medical entitled: Actinogen Medical – Best Risk vs Reward Play in Alzheimer’s Dementia. This report details the investment opportunity presented by ACW, with Baker Young estimating Actinogen Medical’s target share price at $0.39, against the current share price of around $0.06."
I don't think the market has taken much note of Baker Young's research...
